← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
26	ATHX 26 DELISTED Athersys, Inc. Common Stock ATHX	40	+9	+29%	$31.1M
27	27 Veracyte VCYT $3.57B	36	+36	–	$121M
28	NSTG 28 DELISTED NanoString Technologies, Inc. NSTG	28	+7	+33%	$137M
29	29 Imunon IMNN $5.95M	25	-4	-14%	$8.07M
30	30 Arbutus Biopharma ABUS $850M	24	+6	+33%	$39.5M
31	31 Pluri PLUR $11.9M	20	+3	+18%	$1.93M
32	32 Vericel Corp VCEL $2.1B	20	-15	-43%	$1.15M
33	33 Opus Genetics IRD $337M	18	-2	-10%	$2.21M
34	34 Fate Therapeutics FATE $231M	16	+16	–	$24.7M
35	35 DELISTED NeuBase Therapeutics, Inc. Common Stock NBSE	14	+3	+27%	$2.27M
36	36 Eterna Therapeutics ERNA $2.53M	5	+2	+67%	$5.46M
37	37 Qiagen QGEN $9.53B	1	+1	–	$493
38	38 DELISTED Scorpius Holdings, Inc. SCPX	1	0	0%	$5.43M
39	39 Abeona Therapeutics ABEO $266M	–	–	–	–
40	40 Adicet Bio ACET $48.1M	–	–	–	–
41	ACHL 41 DELISTED Achilles Therapeutics ACHL	–	–	–	–
42	42 DELISTED Arcellx ACLX	–	–	–	–
43	ADAP 43 DELISTED Adaptimmune Therapeutics ADAP	–	–	–	–
44	44 Adaptive Biotechnologies ADPT $4.08B	–	–	–	–
45	45 DELISTED Adverum Biotechnologies ADVM	–	–	–	–
46	AGTC 46 DELISTED Applied Genetic Technologies Corporation AGTC	–	–	–	–
47	AKUS 47 DELISTED Akouos Inc AKUS	–	–	–	–
48	48 Allogene Therapeutics ALLO $463M	–	–	–	–
49	49 ALPS Group Inc ALPS $56.4M	–	–	–	–
50	50 ARK Genomic Revolution ETF ARKG $2.09B	–	–	–	–